Gout: from Hippocrates till the modern time

Cover Page

Cite item

Full Text

Abstract

Gout (podagra) is one of the most ancient articular diseases. Its accurate mechanisms and causes were delineated only during the last century. Major historical investigatory steps are described in relation to causality and pathogenesis of the disease from Hippocrates ages till the modern time. The newest genetic and epidemiologic aspects of the disease are presented in this article.

About the authors

Sergei V. Guliaev

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: guldoc@mail.ru
ORCID iD: 0000-0001-6138-4333

канд. мед. наук, доц. каф. внутренних, профессиональных болезней и ревматологии

Russian Federation, Moscow

Natalia V. Chebotareva

Sechenov First Moscow State Medical University (Sechenov University)

Email: guldoc@mail.ru
ORCID iD: 0000-0003-2128-8560

д-р мед. наук, проф. каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского, врач-нефролог Университетской клинической больницы №3

Russian Federation, Moscow

Sergey V. Moiseev

Sechenov First Moscow State Medical University (Sechenov University)

Email: guldoc@mail.ru
ORCID iD: 0000-0002-7232-4640

чл.-кор. РАН, д-р мед. наук, проф. каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского, дир. Клиники ревматологии, нефрологии и профпатологии им. Е.М. Тареева Университетской клинической больницы №3

Russian Federation, Moscow

References

  1. MacKenzie CR. Gout and Hyperuricemia: an Historical Perspective. Curr Treat Options in Rheum. 2015;1:119-30. doi: 10.1007/s40674-015-0012-9
  2. Kittredge WE, Downs R. The role of gout in the formation of urinary calculi. J Urol. 1952;67(6):841-9. doi: 10.1016/s0022-5347(17)68427-1
  3. Nuki G, Simkin PA. Concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8(1):S1. doi: 10.1186/ar1906
  4. Omole OB. The evolution of gout (an old lifestyle disease). South African Family Practice. 2009;51(5):396-8. doi: 10.1080/20786204.2009.10873890
  5. Некрасов Н.А. Полное собрание сочинений и писем в пятнадцати томах. Художественные произведения: в 15 т. Т. 5. Кому на Руси жить хорошо. Л.: Наука, 1982; c. 55 [Nekrasov NA. Polnoie sobraniie sochinenii i pisem v piatnadtsati tomakh. Khudozhestvennyie proizvedeniia: v 15 t. T. 5. Komu na Rusi zhit' khorosho. Leningrad: Nauka, 1982; p. 55 (in Russian)].
  6. McCarty DJ. A historical note: Leeuwenhoek's description of crystals from a gouty tophus. Arthritis Rheum. 1970;13(4):414-8. doi: 10.1002/art.1780130408
  7. Sydenham T. A treatise of the gout and dropsy. London: GGJ, J Robinson. W Otridge, S Hayes and E Newbery, 1683.
  8. Scheele KW. Exam enchemicum calculi urinari. Opuscula. 1776;2:73.
  9. Fourcroy AF. Systême des connaisances chimiques, et leurs applications aux phénomenes de la nature et de l’art. Paris: Baudoin, 1800.
  10. Garrod AB. The Nature and Treatment of Gout and Rheumatic Gout. London: Walton and Maberly, 1859.
  11. Fischer E. Untersuchungen in der Puringruppe. Berlin: Springer, 1907.
  12. Mccarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961;54:452-60. doi: 10.7326/0003-4819-54-3-452
  13. Seegmiller JE, Howell RR, Malawista RE. Inflammatory reaction to sodium urate. Its possible relationship to genesis of acute gouty arthritis. JAMA. 1962;180(6):469-75. doi: 10.1001/jama.1962.03050190031006
  14. Marson P, Pasero G. Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). Reumatismo. 2012;63(4):199-206. doi: 10.4081/reumatismo.2011.199
  15. Gardner MJ, Power C, Barker DJ, Padday R. The prevalence of gout in three English towns. Int J Epidemiol. 1982;11(1):71-5. doi: 10.1093/ije/11.1.71
  16. Hayward RA, Rathod T, Roddy E, et al. The association of gout with socioeconomic status in primary care: a cross-sectional observational study. Rheumatology. 2013;52(11):2004-8. doi: 10.1093/rheumatology/ket262
  17. Rieselbach RE, Sorensen LB, Shelp WD, Steele TH. Diminished renal urate secretion per nephron as a basis for primary gout. Ann Intern Med. 1970;73(3):359-66. doi: 10.7326/0003-4819-73-3-359
  18. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649-62. doi: 10.1038/nrrheum.2015.91
  19. Chen-Xu M, Yokose C, Rai SK, Pillinger MH. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991-9. doi: 10.1002/art.40807
  20. Perheentupa J, Raivio K. Fructose-induced hyperuricaemia. Lancet. 1967;2(7515):528-31. doi: 10.1016/s0140-6736(67)90494-1
  21. Keenan RT, Krasnokutsky S, Pillinger MH. Etiology and Pathogenesis of Hyperuricemia and Gout. In: Firestein GS, Gabriel SE, McInnes IB, O'Dell JR, eds. Kelley & Firestein's textbook of rheumatology. Tenth ed. Philadelphia, PA: Elsevier, 2017; p. 1608-9.
  22. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125(7):679-87.e1. doi: 10.1016/j.amjmed.2011.09.033
  23. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27(6):1501-5.
  24. Tin A, Marten J, Halperin Kuhns VL, et al. Target genes, variants, tissues and transcriptional pathways in fluencing human serum urate levels. Nat Genet. 2019;51(10):1459-74. doi: 10.1038/s41588-019-0504-x
  25. Yang Q, Guo CY, Cupples LA, et al. Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study. Metabolism. 2005;54(11):1435-41. doi: 10.1016/j.metabol.2005.05.007
  26. Punzi L, Scanu A, Ramonda R, Oliviero F. Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets. Autoimmun Rev. 2012;12(1):66-71. doi: 10.1016/j.autrev.2012.07.024
  27. Muiesan ML, Agabiti-Rosei C, Paini A, Salvetti M. Uric Acid and Cardiovascular Disease: An Update. Eur Cardiol. 2016;11(1):54-9. doi: 10.15420/ecr.2016:4:2
  28. Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. doi: 10.1093/eurheartj/ehy339
  29. Kippen I, Whitehouse MW, Klinenberg JR. Pharmacology of uricosuric drugs. Ann Rheum Dis. 1974;33(4):391-6. doi: 10.1136/ard.33.4.391
  30. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273-82. doi: 10.3899/jrheum.080814
  31. Чикина М.Н., Елисеев М.С., Желябина О.В. Практическое применение национальных клинических рекомендаций по лечению подагры (предварительные данные). Современная ревматология. 2020;14(2):97-103 [Chikina MN, Eliseev MS, Zhelyabina OV. Practical application of national clinical guidelines for the management of gout (preliminary data). Sovremennaia revmatologiia. 2020;14(2):97-103 (in Russian)]. doi: 10.14412/1996-7012-2020-2-97-103
  32. Елисеев М.С., Желябина О.В., Мукагова М.В., Насонов Е.Л. Клинический опыт применения блокатора интерлейкина 1β канакинумаба у больных хронической тофусной подагрой: купирование артрита и профилактика обострений при назначении аллопуринола. Современная ревматология. 2015;9(2):16-22 [Eliseev MS, Zhelyabina OV, Mukagova MV, Nasonov EL. Clinical experience with the interleukin 1β blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopuninol is used. Sovremennaia revmatologiia. 2015;9(2):16-22 (in Russian)]. doi: 10.14412/1996-7012-2015-2-16-22
  33. Schlesinger N, Lipsky PE. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. Semin Arthritis Rheum. 2020;50(3S):S31-8. doi: 10.1016/j.semarthrit.2020.04.011

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies